Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Current Leases (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Current Leases for 14 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • Quarterly Current Leases fell 11.61% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, down 11.61% year-over-year, with the annual reading at $1.1 million for FY2025, 11.61% down from the prior year.
  • Current Leases hit $1.1 million in Q4 2025 for Ligand Pharmaceuticals, up from $1.1 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $5.4 million in Q1 2021 to a low of $7000.0 in Q4 2023.
  • Historically, Current Leases has averaged $1.3 million across 5 years, with a median of $1.1 million in 2025.
  • Biggest five-year swings in Current Leases: crashed 97.8% in 2022 and later surged 17985.71% in 2024.
  • Year by year, Current Leases stood at $1.4 million in 2021, then plummeted by 96.71% to $45000.0 in 2022, then plummeted by 84.44% to $7000.0 in 2023, then soared by 17985.71% to $1.3 million in 2024, then fell by 11.61% to $1.1 million in 2025.
  • Business Quant data shows Current Leases for LGNDZ at $1.1 million in Q4 2025, $1.1 million in Q3 2025, and $1.1 million in Q2 2025.